Nomura Holdings Inc. Makes New $693,000 Investment in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Nomura Holdings Inc. purchased a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 6,561 shares of the medical equipment provider's stock, valued at approximately $693,000.

Other large investors have also recently bought and sold shares of the company. Stonebridge Financial Group LLC acquired a new position in shares of Zimmer Biomet during the 4th quarter worth approximately $25,000. Accredited Wealth Management LLC acquired a new position in Zimmer Biomet in the 4th quarter valued at $36,000. Kentucky Trust Co acquired a new position in Zimmer Biomet in the 4th quarter valued at $39,000. OFI Invest Asset Management acquired a new position in Zimmer Biomet in the 4th quarter valued at $40,000. Finally, Dunhill Financial LLC raised its stake in Zimmer Biomet by 86.6% in the 4th quarter. Dunhill Financial LLC now owns 444 shares of the medical equipment provider's stock valued at $47,000 after purchasing an additional 206 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company's stock.

Zimmer Biomet Trading Up 1.3%

ZBH traded up $1.18 during mid-day trading on Friday, hitting $92.85. 3,141,106 shares of the stock were exchanged, compared to its average volume of 1,786,778. The firm's fifty day moving average is $101.84 and its two-hundred day moving average is $105.37. Zimmer Biomet Holdings, Inc. has a 1-year low of $89.92 and a 1-year high of $117.45. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The company has a market cap of $18.37 billion, a PE ratio of 20.86, a PEG ratio of 1.95 and a beta of 0.78.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.04. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. The firm had revenue of $1.91 billion for the quarter, compared to analyst estimates of $1.89 billion. During the same quarter in the prior year, the company earned $1.94 EPS. Zimmer Biomet's revenue was up 1.1% on a year-over-year basis. Equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, April 30th. Investors of record on Monday, March 31st were paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 1.03%. The ex-dividend date was Monday, March 31st. Zimmer Biomet's payout ratio is 21.24%.

Analysts Set New Price Targets

Several research firms recently commented on ZBH. JPMorgan Chase & Co. reduced their price objective on Zimmer Biomet from $128.00 to $105.00 and set an "overweight" rating for the company in a research note on Tuesday, May 6th. Barclays dropped their target price on Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a report on Monday, February 10th. BTIG Research restated a "buy" rating on shares of Zimmer Biomet in a report on Monday, April 14th. Raymond James dropped their target price on Zimmer Biomet from $119.00 to $104.00 and set an "outperform" rating for the company in a report on Tuesday, May 6th. Finally, Robert W. Baird dropped their target price on Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating for the company in a report on Tuesday, May 6th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have given a buy rating to the company. According to MarketBeat, Zimmer Biomet has a consensus rating of "Hold" and an average price target of $111.53.

Insider Buying and Selling

In other news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the transaction, the senior vice president now owns 8,768 shares in the company, valued at approximately $915,379.20. This trade represents a 14.13% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.39% of the stock is owned by corporate insiders.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.